SCHEMBL29445616

SCHEMBL29445616

CC[C@H](C)[C@@H](C=O)NC(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 4/20 0.51
▸ KMT2A Q03164 2/20 0.48
▸ EPHX2 P34913 1/20 0.46
▸ MDM4 O15151 2/20 0.44
▸ TP53 P04637 2/20 0.44
▸ PIN1 Q13526 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13652772 1.00 CASP3 (0.51) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL29445597 0.89 CASP3 (0.54) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL15929330 0.89 CASP3 (0.54) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL14581384 0.89 CASP3 (0.54) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL31453048 0.88 CASP3 (0.53) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL15223382 0.88 CASP3 (0.53) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL10187000 0.85 CASP3 (0.60) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL13570148 0.85 CASP3 (0.60) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL13452269 0.84 CASP3 (0.56) CASP3KMT2AEPHX2MDM4TP53
SCHEMBL5021152 0.84 CASP3 (0.56) CASP3KMT2AEPHX2MDM4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115594769-B Modular assembly technology of cell-penetrating peptide-mediated polypeptide or micro-protein targeting chimeric and application thereof 刘淼 2026-05-15 — — CN disclosed
US-20260132172-A1 IN VITRO BIOSYNTHESIS OF DIVERSE PYRIDINE-BASED MACROCYCLIC PEPTIDES The Brd. of Trustees of the Univ. of Illinois (US) 2026-05-14 — — US disclosed
CN-120665149-B Key preparation method of bird's nest peptide and bird's nest peptide for pregnant women 燕鸿基健康美(厦门)食品有限公司 2026-02-27 — — CN disclosed
US-12492225-B2 Melanocyte-regulating peptides IDP DISCOVERY PHARMA, S.L. (ES) 2025-12-09 — — US disclosed
CN-119978065-A Antibacterial peptide Loong-3 and application thereof 河南科技学院 2025-05-13 — — CN disclosed
EP-4532513-A1 CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS Fundación Privada Instituto De Salud Global Barcelona (ES) 2025-04-09 — — EP disclosed
CN-119451974-A Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens 巴塞罗那全球健康研究所私人基金会 2025-02-14 — — CN disclosed
CN-118853625-A Antibacterial polypeptide APH76 and preparation method and application thereof 南京华盖制药有限公司 2024-10-29 — — CN disclosed
CN-118754964-A Amphiphilic cationic antibacterial neuropeptide and application thereof 中国科学院宁波材料技术与工程研究所 2024-10-11 — — CN disclosed
US-20240294573-A1 CONSTRAINED PEPTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-09-05 — — US disclosed
WO-2022144401-A1 VEGF-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2022-07-07 — — WO disclosed
EP-4023295-A1 VEGF-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2022-07-06 — — EP disclosed
EP-4007563-A1 MELANOCYTE-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2022-06-08 — — EP disclosed
US-11352395-B2 Anticancer peptides IDP DISCOVERY PHARMA, S.L. (ES) 2022-06-07 — — US disclosed
WO-2022106825-A1 COMPOSITIONS UNIVERSITY OF SOUTHAMPTON (GB) 2022-05-27 — — WO disclosed
CN-114409737-A Novel anti-tumor peptide and application thereof 南阳师范学院 2022-04-29 — — CN disclosed
EP-3986914-A1 CONSTRAINED PEPTIDES TearSolutions, Inc. (US) 2022-04-27 — — EP disclosed
CN-114245800-A Melanocyte regulatory peptides IDP研发制药有限公司 2022-03-25 — — CN disclosed
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2022-03-22 — — US disclosed
CN-114206916-A Restricted peptides 缇尔索卢森公司 2022-03-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492225-B2 Melanocyte-regulating peptides MC1R, MITF, MCHR1 CASP3 4704/4885KMT2A 995/4885EPHX2 3556/4885
US-20260132172-A1 IN VITRO BIOSYNTHESIS OF DIVERSE PYRIDINE-BASED MACROCYCLIC PEPTIDES MLX, PDHX, DLD CASP3 4152/4885KMT2A 1987/4885EPHX2 888/4885
US-11279734-B2 Solution-phase affinity selection of inhibitors from combinatorial peptide libraries TP53, MDM2, MDM4 CASP3 2615/4885KMT2A 3182/4885EPHX2 3865/4885
US-20240294573-A1 CONSTRAINED PEPTIDES IAPP, NGLY1, VIP CASP3 1870/4885KMT2A 4628/4885EPHX2 4431/4885
US-11352395-B2 Anticancer peptides PNISR, NGLY1, SLC1A5 CASP3 2512/4885KMT2A 1904/4885EPHX2 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback